The short answer
GLP-2 is a 33-amino-acid peptide released from gut endocrine cells alongside GLP-1, from the same precursor protein. It promotes growth of the intestinal mucosa rather than affecting glucose or appetite, and its analogue teduglutide is licensed for short bowel syndrome.
Key facts
- Length
- 33 amino acids
- Source
- Gut endocrine cells, co-secreted with GLP-1
- Precursor
- Proglucagon, the same gene as GLP-1 and glucagon
- Principal described action
- Intestinal growth-promoting activity
- Receptor
- GLP-2 receptor, distinct from the GLP-1 receptor
- Inactivating enzyme
- DPP-4
- Licensed analogue
- Teduglutide
- Pivotal trial
- STEPS, NCT00798967, Phase 3, 86 participants, 24 weeks
Discovered by accident, like several of the best things here
Drucker's own account of the discovery describes it as following serendipitous observations that proglucagon-producing tumours induced intestinal growth in mice. That is a useful reminder about how this field advances: the observation came first and the mechanism was worked backwards from it. A tumour secreting the products of one gene made the gut grow, which meant one of those products had a growth-promoting action nobody had assigned to it. GLP-2 was the answer, and it is a 33-amino-acid peptide co-secreted with GLP-1 from the same gut endocrine cells.
Two peptides from one cell doing unrelated things
GLP-1 and GLP-2 are released together, from the same cell, in response to the same stimulus. GLP-1 acts on insulin secretion, gastric emptying and appetite. GLP-2 acts on the intestinal mucosa itself, promoting growth of the absorptive surface. They engage different receptors, and the GLP-2 receptor had to be cloned separately before development could proceed. The pairing is coherent if you think about what an L cell is reporting: nutrients have arrived. One response is to handle the nutrients metabolically, the other is to expand the apparatus that absorbs them.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The DPP-4 problem, and the one-residue solution
Drucker names the recognition of dipeptidyl peptidase-4 as a critical determinant of GLP-2 bioactivity among the key developments enabling pharmaceutical work. GLP-2, like GLP-1, is cleaved and inactivated by DPP-4, which cuts after the second residue when that residue is alanine or proline. Teduglutide is described as a simple GLP-2 analogue: the substitution of a single amino acid at position two removes the DPP-4 recognition site, and the resulting molecule survives long enough to be given once daily. The same enzymatic vulnerability and the same class of fix appear across this whole peptide family, which is why understanding DPP-4 explains the shape of so many of these molecules.
What teduglutide is licensed for
Short bowel syndrome, a condition in which so much intestine has been lost that absorption is inadequate and patients depend on parenteral nutrition. The pivotal STEPS trial is registered as NCT00798967: a Phase 3, quadruple-masked, 24-week study of 86 participants with parenteral-nutrition-dependent short bowel syndrome, with a responder analysis as its primary outcome. The clinically meaningful endpoint in this condition is reduction in the volume of parenteral support required, and a later analysis by Jeppesen and colleagues found that response was associated with baseline parenteral support volume, bowel anatomy and disease features, in particular whether the colon remained in continuity. That is a small trial by obesity standards and a substantial one for a rare disease.
Why the growth effect is the interesting risk
A drug whose mechanism is promoting growth of intestinal mucosa raises an obvious question about growth that is not wanted, and that question belongs to the prescribing information and to specialist practice rather than to a reference article. The general point worth making is that GLP-2's mechanism is trophic in a way GLP-1's is not, and that this is the sharpest illustration available of why two peptides from the same precursor released by the same cell cannot be discussed as though they were interchangeable.
Where GLP-2 sits in current development
Interest in combining GLP-1 and GLP-2 activity in one molecule exists, on the reasoning that the precursor already pairs them. Whether that produces anything useful is unsettled. Teduglutide is a licensed medicine prescribed and monitored for a serious condition; it is not supplied on this site, nothing sold here is a version of it, and it is not relevant to weight management in any way. It appears in this library because it is the proof that a proglucagon-derived peptide other than GLP-1 can become a real medicine.
Frequently asked questions
Is GLP-2 involved in weight loss?
No. Its described action is on the intestinal mucosa, not on appetite or glucose. Marketing that groups it with GLP-1 because of the shared name is trading on a similarity that does not extend to what the peptides do.
Do GLP-1 receptor agonists activate the GLP-2 receptor?
They are separate receptors and the agonists in clinical use are selective for their own. The peptides are related by precursor, not by receptor, which is why the GLP-2 receptor had to be cloned independently.
Why is the STEPS trial so small?
Because short bowel syndrome with parenteral nutrition dependence is rare. Trial size is set by how many eligible patients exist, and 86 participants in a quadruple-masked randomised trial is substantial evidence in that context, even though the same number would be a Phase 2 in obesity.
Can GLP-2 be bought as research material?
It is not supplied on this site. Teduglutide is a licensed prescription medicine and is not a research chemical. Anything sold under either name outside a pharmacy is not the licensed product.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDrucker DJ, The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome - ACS Pharmacol Transl Sci 2019 (PMID 32219218)pubmed.ncbi.nlm.nih.gov
- PubMedJeppesen PB et al., Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure - Gastroenterology 2018 (PMID 29174926)pubmed.ncbi.nlm.nih.gov
- TrialSTEPS teduglutide Phase 3 registry record (NCT00798967)clinicaltrials.gov
- PubMedLafferty RA et al., Proglucagon-Derived Peptides as Therapeutics - Front Endocrinol 2021 (PMID 34093449)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- A Risk Ratio of 0.57 That Means Almost NothingOne meta-analysis reported RR 0.568 for suicidality with GLP-1 drugs. Its interval ran from 0.077 to 4.205, which is compatible with almost any answer.
- Adding a Warning Needs Suspicion; Removing One Needs EvidenceRegulators added a suicidality warning to GLP-1 labels on suspicion alone. Removing it again took two and a half years and a review of 91 randomised trials.
- The Receptors That Decide When GLP-1 Comes OutGlucose, fat and fermentation products are each detected by a different sensor on the same cell, and none of them works quite the way most explanations assume.
- The Nerve That Reads GLP-1 Before the Blood DoesKnocking down GLP-1 receptors on vagal afferents changed meal size and gastric emptying but not long-term body weight. That distinction matters enormously.
- Why Where Bile Arrives Changes How Much GLP-1 Comes OutBile acids are signalling molecules as well as detergents. They act on a receptor on L cells, and delivering them further down the gut raises the response.